Literature DB >> 21144991

Antibiotic de-escalation.

Robert G Masterton1.   

Abstract

Antibiotic de-escalation is a mechanism whereby the provision of effective initial antibiotic treatment is achieved while avoiding unnecessary antibiotic use that would promote the development of resistance. It is a key element within antimicrobial stewardship programs and treatment paradigms for serious sepsis. The embodiment of de-escalation is that based on microbiology results around the day 3 therapy point; the empiric antibiotic(s) that were started are stopped or reduced in number and/or narrowed in spectrum. Data are presented here which demonstrate that de-escalation is clinically effective and appropriate. However, the need for further studies, particularly in terms of realization of full benefits as well as implementation tools, is highlighted. De-escalation ought now to form a part of routine antimicrobial management, though how best to do it and the full breadth and scope of benefits remain to be identified.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21144991     DOI: 10.1016/j.ccc.2010.09.009

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  41 in total

Review 1.  Bloodstream infections in the Intensive Care Unit.

Authors:  Matteo Bassetti; Elda Righi; Alessia Carnelutti
Journal:  Virulence       Date:  2016-01-13       Impact factor: 5.882

Review 2.  Gene Expression Profiles in Children With Suspected Sepsis.

Authors:  Fran Balamuth; Elizabeth R Alpern; Mengyuan Kan; Maya Shumyatcher; Katie Hayes; Ebbing Lautenbach; Blanca E Himes
Journal:  Ann Emerg Med       Date:  2020-01-23       Impact factor: 5.721

Review 3.  De-escalating Antibiotic Use in the Inpatient Setting: Strategies, Controversies, and Challenges.

Authors:  J Daniel Markley; Shaina Bernard; Gonzalo Bearman; Michael P Stevens
Journal:  Curr Infect Dis Rep       Date:  2017-04       Impact factor: 3.725

4.  Assessment of Rapid-Blood-Culture-Identification Result Interpretation and Antibiotic Prescribing Practices.

Authors:  Linsey M Donner; W Scott Campbell; Elizabeth Lyden; Trevor C Van Schooneveld
Journal:  J Clin Microbiol       Date:  2017-03-01       Impact factor: 5.948

5. 

Authors:  Y Moutaouakkil; S Siah; A Bennana; Y Tadlaoui; S Makram; Y Cherrah; Y Bousliman; J Lamsaouri
Journal:  Ann Burns Fire Disasters       Date:  2018-03-31

6.  Variability in Diagnosis and Treatment of Ventilator-Associated Pneumonia in Neurocritical Care Patients.

Authors:  Atul A Kalanuria; Donna Fellerman; Paul Nyquist; Romergryko Geocadin; Robert G Kowalski; Veronique Nussenblatt; Matthew Rajarathinam; Wendy Ziai
Journal:  Neurocrit Care       Date:  2015-08       Impact factor: 3.210

7.  Development of an antibiotic spectrum score based on veterans affairs culture and susceptibility data for the purpose of measuring antibiotic de-escalation: a modified Delphi approach.

Authors:  Karl Madaras-Kelly; Makoto Jones; Richard Remington; Nicole Hill; Benedikt Huttner; Matthew Samore
Journal:  Infect Control Hosp Epidemiol       Date:  2014-07-25       Impact factor: 3.254

8.  Assessment of empirical antibiotic therapy optimisation in six hospitals: an observational cohort study.

Authors:  Nikolay P Braykov; Daniel J Morgan; Marin L Schweizer; Daniel Z Uslan; Theodoros Kelesidis; Scott A Weisenberg; Birgir Johannsson; Heather Young; Joseph Cantey; Arjun Srinivasan; Eli Perencevich; Edward Septimus; Ramanan Laxminarayan
Journal:  Lancet Infect Dis       Date:  2014-11-17       Impact factor: 25.071

9.  Piperacillin-Tazobactam Usage at a Tertiary Pediatric Hospital: An Antimicrobial Stewardship Review.

Authors:  Andrew B Janowski; Marian G Michaels; Judith M Martin; Michael D Green
Journal:  J Pediatric Infect Dis Soc       Date:  2015-07-13       Impact factor: 3.164

10.  Antimicrobial de-escalation of treatment for healthcare-associated pneumonia within the Veterans Healthcare Administration.

Authors:  Karl Madaras-Kelly; Makoto Jones; Richard Remington; Christina M Caplinger; Benedikt Huttner; Barbara Jones; Matthew Samore
Journal:  J Antimicrob Chemother       Date:  2015-11-03       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.